

DEC 09 2003

Certificate of Mailing by Express Mail

Express Mail Label No.: EV 312852397 US

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 and is addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on the date indicated below.

By: Barbara Bryant
Barbara Bryant

Date: December 8, 2003

Patent
Attorney's Docket No. P-108-US2
Customer No. 27038

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)	
)	
CHOI et al.)	Group Art Unit: 1614
)	
Application No.: 10/659,931)	Examiner: Not yet assigned
)	
Filed: September 11, 2003)	
)	
For: SODIUM CHANNEL)	
MODULATORS)	

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 CFR §1.56, Applicants hereby submit the following information in conformance with CFR §§1.97 and 1.98. Enclosed herewith is form PTO-1449 which lists the documents being submitted for consideration by the Examiner. Copies of the cited documents are also enclosed herewith.

The filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made (37 C.F.R. §1.97(g)), or as an admission that the information cited is, or is considered to be, material to patentability (37 C.F.R. §1.97(h)).

Pursuant to 37 C.F.R. §1.98(a)(3)(i), concise explanations of the relevance of the following non-English language document is provided:

(1) FR 2 496 653 (in French language) discloses heterocyclic aminoalcoyl derivatives useful as drugs, especially analgesics and antidepressants. To the best of Applicant's knowledge, U. S. Patent No. US 4,386,090, listed as Citation A2 on the accompanying PTO form 1449, is an English language translation of FR 2 496 653, listed as Citation B3.

Consideration of the listed documents is respectfully requested. Additionally, the Examiner is respectfully requested to return an initialed copy of the enclosed form PTO-1449 to Applicants.

This Information Disclosure Statement is being filed before the mailing date of a first official action on the merits for this application and therefore, no fee or certification is required under 37 CFR §1.97(b). In the event that an Office Action is mailed prior to receipt of this paper, the Commissioner is hereby authorized to charge the requisite fees under 37 CFR §1.97(c) for submission of this paper to Deposit Account No. 50-0344.

Should there be any questions concerning the cited documents, the Examiner is encouraged to telephone the undersigned agent for Applicants at (650) 808-6406 (direct).

Respectfully submitted,


THERAVANCE, INC.

Date: December 8, 2003

By: Roberta P. Saxon

Roberta P. Saxon, Ph. D.
Registration No. 43,087

THERAVANCE, INC.
901 Gateway Boulevard
South San Francisco, CA 94080
Tel: (650) 808-6000
Fax: (650) 808-6078



PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	10/659,931
Filing Date	September 11, 2003
First Named Inventor	Seok-Ki CHOI
Art Unit	1614
Examiner Name	Not yet assigned
Attorney Docket Number	P-108-US2

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	A1	US- 4,140,779	02-20-1979	Ferland et al.	
	A2	US- 4,386,090	05-31-1983	Moinet et al.	
	A3	US- 5,688,830	11-18-1997	Berger et al.	
	A4	US- 5,985,933	11-16-1999	Zeitlin et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	B1	WO 97/27169 A1	07-31-1997	F. Hoffmann-La Roche AG		
	B2	EP 0 869 119 A1	10-07-1998	F. Hoffmann-La Roche AG		
	B3	FR 2 496 653 (in French language)	06-25-1982	Delalande SA		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	DE LUCA et al., "Molecular Determinants of Mexiletine Structure for Potent and Use-Dependent Block of Skeletal Muscle Sodium Channels", Molecular Pharmacology, Vol. 57, pp 268-277 (2000)	
	C2	HUNTER et al., "Voltage-gated sodium channel blockers for the treatment of chronic pain", Current Opinion in CPNS Investigational Drugs, Vol. 1(1), pp 72-81 (1999)	
	C3	LOUGHHEAD et al., "Synthesis of Mexiletine Stereoisomers and Related Compounds via S _N Ar Nucleophilic Substitution of a Cr(CO) ₃ -Complexed Aromatic Fluoride", J. Org. Chem., Vol. 64, pp 3373-3375 (1999)	
	C4	MADGE, "Chapter 6. Sodium Channels: Recent Developments and Therapeutic Potential", Annual Reports in Medicinal Chemistry, pp 51-59 (1998)	
	C5	ROUFOS et al., "A Structure-Activity Relationship Study of Novel Phenylacetamides Which Are Sodium Channel Blockers", J. Med. Chem., Vol. 39, pp 1514-1520 (1996)	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.